Abstract:Background: Each year, billions of dollars are spent globally on infectious disease research and development (R&D). However, there is little systematic tracking of global R&D.Methods: The study examined research awards made between 2000 and 2017 for infectious disease research from G20-based public and philanthropic funders. Research databases were searched using a range of keywords, and open data was extracted from funder websites. Awards were categorised by type of science, specialty, and disease/pathogen. Data collected included study title, abstract, award amount, funder, and year. Descriptive statistics and regression analyses were used to investigate the relationship between research investment and disease burden, using Global Burden of Disease 2017 study data.Findings: There was $104.9 billion (b) investment across 94 074 awards (annual range $4.1 to $8.4b). Pre-clinical research received $61.1b (58.2%) and public health research $29.5b (28.1%). HIV/AIDS received $42.1b (40.1%), tuberculosis $7.0b (6.7%), malaria $5.6b (5.3%) and pneumonia $3.5b (3.3%). Funding for Ebola ($1.2b), Zika ($0.3b), influenza ($4.4b) and coronavirus ($0.5b) was typically highest soon after a high-profile outbreak. There was a general increase in year-on-year investment between 2000 and 2006, with decline between 2007 and 2017. Funders based in the United States of America provided $81.6b (77.8%). On the basis of funding per 2017 disability-adjusted life years (DALYs), HIV/AIDS received greatest relative investment ($772/DALY), compared with tuberculosis ($156/DALY), malaria ($125/DALY), and pneumonia ($33/DALY). Syphilis and scabies received the least relative investment ($9/DALY). There was a weak positive relationship (Spearman’s correlation coefficient [r] 0.30) between investment and 2017 disease burden.Interpretation: HIV research received highest amount of investment relative to DALY burden. Scabies and syphilis received lowest relative funding. Investments for high-threat pathogens (e.g. Ebola, Coronavirus) were often reactive, following outbreaks. There was little evidence that funding is guided by global burden or pandemic risk. The study findings show how research investments are allocated currently and how these relate to disease burden and to conditions with pandemic potential.Funding: None.Declaration of Interest: No conflicts of interest to declare.

The Extended Impact of Human Immunodeficiency Virus/AIDS Research

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus

Recent Insights into the HIV/AIDS Pandemic

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis

The Changing Science of HIV Epidemiology in the United States

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects

The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 Countries

Economic evaluation studies in the field of HIV/AIDS: bibliometric analysis on research development and scopes (GAPRESEARCH)

Characterizing the Development of Research Landscapes in Substance Use and HIV/AIDS During 1990 to 2021

Investment in HIV/AIDS Programs: Does It Help Strengthen Health Systems in Developing Countries?

The emergence and evolution of the research fronts in HIV/AIDS research

The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.

Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas

Trends in Investment for Research and Development of AIDS Vaccines

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence

Advanced Therapies for Human Immunodeficiency Virus

A bibliometric analysis of HIV nursing research between 1999 and 2022

Immune Activation and Collateral Damage in AIDS Pathogenesis

HIV/AIDS epidemiology, pathogenesis, prevention, and treatment